证券日报网讯12月25日，新华医疗（600587）在互动平台回答投资者提问时表示，截至2025年11月25 日，公司控股股东已累计增持386.38万股，增持金额6011.35万元。控股股东将继续根据资本市场整体情 况、公司股价波动及自身资金安排，在合规前提下择机推进后续增持工作。 ...

Core Viewpoint - Xinhua Medical has received medical device registration certificates from the National Medical Products Administration and the Shandong Provincial Medical Products Administration for its products [1] Group 1 - Xinhua Medical announced the receipt of medical device registration certificates for both the company and its wholly-owned subsidiary, Shandong Xinhua Blood Technology Co., Ltd. [1]

证券日报网讯12月25日，新华医疗（600587）在互动平台回答投资者提问时表示，公司实际控制人为山 东省人民政府国有资产监督管理委员会。 ...

Group 1 - Guangdong Construction signed an EPC contract worth 416 million yuan, with a total construction area of 99,595.6 square meters and a construction period of 640 calendar days [1] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [2] - Jinbei Automotive signed a memorandum of understanding with E-Works to establish a research and development center for electric light commercial vehicles [3] Group 2 - Hongsheng Huayuan is expected to win approximately 569 million yuan in procurement projects from the State Grid, which represents about 5.61% of the company's projected revenue for 2024 [4] - Zhongding Co. plans to establish a joint venture for humanoid robot manufacturing with a registered capital of 50 million yuan [5] - Kede CNC's new factory in Shenyang is expected to achieve an annual production capacity of about 60 units [6] Group 3 - Hongbo Pharmaceutical's share transfer price is set at 25.27 yuan per share [7] - ST Jinglan plans to sign a letter of intent for the acquisition of Xinlian Environmental Technology Co., enhancing its core technology competitiveness [8][9] - Hato Co. announced the resignation of its general manager due to job relocation [10] Group 4 - Meibang Co. plans to apply for a new bank credit line of up to 160 million yuan [11] - Southern Media's general manager resigned due to job relocation [12] - Dalian Electric Porcelain's subsidiary is expected to win procurement projects from the State Grid worth approximately 70.7 million yuan [13] Group 5 - Sinopharm Modern's subsidiary received a drug registration certificate for a new medication [14] - ST Meigu plans to implement a capital reserve transfer to increase share capital, leading to a one-day stock suspension [15] - Ruisheng Intelligent confirmed a transaction of 152 million yuan for domestic computing equipment procurement [16] Group 6 - Jinguang Electric won three procurement packages from the State Grid, totaling 37.43 million yuan [17] - Guangju Energy increased its stake in Mawan Power to 14.42% by acquiring an 8% share for 680 million yuan [18][19] - ST Lingda announced a stock suspension due to capital reserve transfer related to its restructuring plan [20] Group 7 - Suli Co. plans to increase its investment in Suli Ningxia by 76.63 million yuan [21] - Dalian Shengya's subsidiary plans to reduce its registered capital by 32.37 million yuan [22] - Yinxin Technology received a cash dividend of 11.05 million yuan from its subsidiary [23] Group 8 - Haike New Source signed a three-year supply agreement for 270,000 tons of electrolyte materials [24] - Xinhua Medical received registration certificates for several medical devices [25] - Wantai Bio received a registration certificate for an HIV antibody testing kit [26] Group 9 - Beilu Pharmaceutical obtained a drug registration certificate for a new erectile dysfunction treatment [31] - Zhongwei Company is planning to issue shares to acquire assets, leading to a stock suspension [32] - Zhejiang Haideman plans to purchase land for strategic development, with a budget of up to 260 million yuan [33] Group 10 - Ningbo Ocean announced the resignation of its deputy general manager due to job adjustments [34] - Tongguang Cable is expected to win procurement projects from the State Grid worth over 139 million yuan [35]

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-065 山东新华医疗器械股份有限公司 关于公司产品获得三类和二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）及全资 子公司山东新华血液技术有限公司于近日收到国家药品监督管理局和山东省药品 监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 （一）血液透析器 1、产品名称：血液透析器 2、注册证编号：国械注准 20253102637 3、注册人名称：山东新华血液技术有限公司 4、注册人住所：山东省淄博市周村区新华大道 2009 号新华医疗科技园 E 区 E2-1-1#厂房 101 室 5、生产地址：山东省淄博市周村区新华大道 2009 号新华医疗科技园 E 区 E2-1-1#厂房 6、结构及组成：本产品主要由外壳、端盖、透析膜、密封胶与密封塞组成。 本产品采用电子束辐照灭菌，一次性使用。 7、型号、规格：CLEAR 15H，C ...

证券日报网讯12月23日，新华医疗（600587）在互动平台回答投资者提问时表示，公司长期关注脑机接 口技术在康复领域的应用潜力，重点推进该技术与现有运动康复、认知康复设备的产品融合与技术升 级。目前，公司已启动脑机接口与康复设备结合的初代样机研发，未来将进一步拓展其在康复评估与训 练中的实际应用。 ...

Group 1 - The company has initiated self-research and development in the fields of brain-computer interfaces and exoskeleton robots [1] - The expansion into new sectors will adhere to principles of main business synergy and controllable risks, with a cautious approach to mergers and acquisitions as well as technology transformation [1] - The company will continue to focus on technology transformation related to new productive forces and the identification of quality targets, aiming to maintain long-term value and shareholder interests [1]

Group 1 - The core viewpoint of the article is that Xinhua Medical has decided to reduce its holdings in Huajian Medical due to various uncertainties, including trading volume, liquidity, and regulatory rules [2] Group 2 - Xinhua Medical's decision to divest is influenced by the trading volume and liquidity of Huajian Medical [2] - The company is also considering regulatory rules as a factor in its decision-making process [2]

（文章来源：证券日报） 证券日报网讯 12月23日，新华医疗在互动平台回答投资者提问时表示，2025年三季度业绩出现波动， 主要受投资收益及其他收益减少，以及研发投入加大等多重因素综合影响。公司详细经营情况敬请关注 公司定期报告。 ...

格隆汇12月23日丨新华医疗(600587.SH)在投资者互动平台表示，公司长期关注脑机接口技术在康复领 域的应用潜力，重点推进该技术与现有运动康复、认知康复设备的产品融合与技术升级。目前，公司已 启动脑机接口与康复设备结合的初代样机研发，未来将进一步拓展其在康复评估与训练中的实际应用。 ...